The news of Stifel maintaining a Buy rating on Neurocrine Biosciences is positive for the stock. However, the lowering of the price target from $145 to $125 may create some uncertainty among investors. The overall impact on the stock price in the short term is expected to be neutral as the positive and negative factors balance each other out.